Robeco Institutional Asset Management B.V. lowered its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) by 47.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 30,265 shares of the biotechnology company’s stock after selling 27,269 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in BioMarin Pharmaceutical were worth $3,132,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in BioMarin Pharmaceutical by 1.6% in the third quarter. Vanguard Group Inc. now owns 17,108,289 shares of the biotechnology company’s stock valued at $1,450,270,000 after buying an additional 263,453 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in BioMarin Pharmaceutical by 2.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,128,030 shares of the biotechnology company’s stock worth $86,972,000 after purchasing an additional 27,091 shares in the last quarter. Balyasny Asset Management LLC grew its holdings in BioMarin Pharmaceutical by 39.2% in the third quarter. Balyasny Asset Management LLC now owns 785,788 shares of the biotechnology company’s stock valued at $66,611,000 after purchasing an additional 221,090 shares during the period. Pictet Asset Management SA increased its position in shares of BioMarin Pharmaceutical by 56.3% in the third quarter. Pictet Asset Management SA now owns 768,367 shares of the biotechnology company’s stock valued at $65,135,000 after buying an additional 276,664 shares in the last quarter. Finally, Frontier Capital Management Co. LLC raised its stake in shares of BioMarin Pharmaceutical by 24.5% during the 3rd quarter. Frontier Capital Management Co. LLC now owns 759,540 shares of the biotechnology company’s stock worth $64,386,000 after buying an additional 149,238 shares during the period. Hedge funds and other institutional investors own 96.26% of the company’s stock.
Insider Activity at BioMarin Pharmaceutical
In other BioMarin Pharmaceutical news, CEO Jean Jacques Bienaime sold 15,000 shares of BioMarin Pharmaceutical stock in a transaction dated Friday, February 10th. The stock was sold at an average price of $110.11, for a total value of $1,651,650.00. Following the completion of the transaction, the chief executive officer now directly owns 320,324 shares of the company’s stock, valued at approximately $35,270,875.64. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other BioMarin Pharmaceutical news, CEO Jean Jacques Bienaime sold 15,000 shares of the business’s stock in a transaction on Friday, February 10th. The shares were sold at an average price of $110.11, for a total value of $1,651,650.00. Following the completion of the transaction, the chief executive officer now owns 320,324 shares in the company, valued at $35,270,875.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director V Bryan Lawlis sold 8,500 shares of the stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $97.09, for a total value of $825,265.00. Following the completion of the sale, the director now owns 28,950 shares in the company, valued at $2,810,755.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 72,500 shares of company stock worth $7,196,515. 1.75% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
BioMarin Pharmaceutical Stock Performance
Shares of BioMarin Pharmaceutical stock opened at $95.45 on Friday. The firm has a market cap of $17.91 billion, a PE ratio of 251.18 and a beta of 0.38. The company has a quick ratio of 3.15, a current ratio of 4.67 and a debt-to-equity ratio of 0.24. BioMarin Pharmaceutical Inc. has a 52 week low of $70.73 and a 52 week high of $117.77. The business’s fifty day simple moving average is $95.50 and its 200-day simple moving average is $99.36.
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) last issued its quarterly earnings data on Monday, February 27th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.01). The company had revenue of $537.54 million during the quarter, compared to analysts’ expectations of $533.88 million. BioMarin Pharmaceutical had a net margin of 3.30% and a return on equity of 4.04%. Equities analysts forecast that BioMarin Pharmaceutical Inc. will post 1.06 earnings per share for the current year.
BioMarin Pharmaceutical Profile
BioMarin Pharmaceutical, Inc engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M.
Read More
- Get a free copy of the StockNews.com research report on BioMarin Pharmaceutical (BMRN)
- Investors Are Barking Up The Right Tree With Datadog
- How to Invest in Central Bank Digital Currency
- Kellogg Company Looks GRRR-eat! At These Levels
- PacWest, First Horizon Shares Plummet On Continued Bank Worries
- Yum! Brands Pulls Back To More Appetizing Levels
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
